Compare Stocks: PGEN, ABVX, PRAX, and KYMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$118.64 +2.3%	$124.83	$69.81 ▼ $148.83	$10.12B	0.96	907,979 shs	893,423 shs
KYMR Kymera Therapeutics	$114.96 -1.7%	$114.48	$45.84 ▼ $130.05	$9.73B	1.96	601,202 shs	574,184 shs
PGEN Precigen	$6.85 +2.5%	$6.32	$2.99 ▼ $7.72	$2.44B	1.02	4.30 million shs	2.06 million shs
PRAX Praxis Precision Medicines	$334.58 -1.2%	$340.54	$37.24 ▼ $392.70	$9.45B	2.76	310,168 shs	173,532 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+2.32%	+3.35%	-5.48%	+22.88%	+35.39%
KYMR Kymera Therapeutics	-1.74%	-2.07%	+0.82%	+33.35%	+164.40%
PGEN Precigen	+2.54%	-3.52%	0.00%	+53.93%	+67.89%
PRAX Praxis Precision Medicines	-1.18%	-4.90%	-13.40%	+25.51%	+731.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$118.64 +2.3%	$124.83	$69.81 ▼ $148.83	$10.12B	0.96	907,979 shs	893,423 shs
KYMR Kymera Therapeutics	$114.96 -1.7%	$114.48	$45.84 ▼ $130.05	$9.73B	1.96	601,202 shs	574,184 shs
PGEN Precigen	$6.85 +2.5%	$6.32	$2.99 ▼ $7.72	$2.44B	1.02	4.30 million shs	2.06 million shs
PRAX Praxis Precision Medicines	$334.58 -1.2%	$340.54	$37.24 ▼ $392.70	$9.45B	2.76	310,168 shs	173,532 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+2.32%	+3.35%	-5.48%	+22.88%	+35.39%
KYMR Kymera Therapeutics	-1.74%	-2.07%	+0.82%	+33.35%	+164.40%
PGEN Precigen	+2.54%	-3.52%	0.00%	+53.93%	+67.89%
PRAX Praxis Precision Medicines	-1.18%	-4.90%	-13.40%	+25.51%	+731.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.88	Moderate Buy	$156.38	31.81% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$130.83	13.81% Upside
PGEN Precigen	2.80	Moderate Buy	$14.50	111.68% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$585.95	75.13% Upside

Current Analyst Ratings Breakdown

Latest PGEN, ABVX, PRAX, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	KYMR Kymera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$180.00
9/9/2026	ABVX Abivax	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$155.00
9/9/2026	ABVX Abivax	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/31/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $170.00
8/27/2026	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$116.00 ➝ $151.00
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	KYMR Kymera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/7/2026	PRAX Praxis Precision Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$449.00 ➝ $462.00
8/7/2026	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$514.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
KYMR Kymera Therapeutics	$105M	91.04	N/A	N/A	$19.42 per share	5.92
PGEN Precigen	$85.72M	28.49	N/A	N/A	$0.06 per share	114.17
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	$34.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	7.97	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)

Latest PGEN, ABVX, PRAX, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9170	N/A	N/A	N/A	$0.80 million	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
KYMR Kymera Therapeutics	N/A	10.34	10.34
PGEN Precigen	2.15	4.58	3.89
PRAX Praxis Precision Medicines	N/A	15.73	15.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
KYMR Kymera Therapeutics	N/A
PGEN Precigen	33.51%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
KYMR Kymera Therapeutics	15.98%
PGEN Precigen	41.40%
PRAX Praxis Precision Medicines	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	69	87.25 million	N/A	Not Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable
PGEN Precigen	47	356.51 million	208.92 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable

PGEN, ABVX, PRAX, and KYMR Headlines

Recent News About These Companies

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

September 12 at 11:00 AM | seekingalpha.com

8,060 Shares in Praxis Precision Medicines, Inc. $PRAX Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

September 11 at 4:55 AM | marketbeat.com

California State Teachers Retirement System Grows Position in Praxis Precision Medicines, Inc. $PRAX

September 11 at 3:51 AM | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Bought Rep. Gilbert Ray Cisneros, Jr.

September 8, 2026 | marketbeat.com

Readystate Asset Management LP Takes $3.53 Million Position in Praxis Precision Medicines, Inc. $PRAX

September 7, 2026 | marketbeat.com

Seven Fleet Capital Management LP Acquires Shares of 7,540 Praxis Precision Medicines, Inc. $PRAX

September 5, 2026 | marketbeat.com

PRAX stock reacts to new Nasdaq inducement grants

September 4, 2026 | ad-hoc-news.deA

Wellington Management Group LLP Sells 48,483 Shares of Praxis Precision Medicines, Inc. $PRAX

September 4, 2026 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

Praxis Precision Medicines, Inc. $PRAX is Velan Capital Investment Management LP's Largest Position

September 2, 2026 | marketbeat.com

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

August 31, 2026 | barrons.com

Bank of New York Mellon Corp Makes New $28.58 Million Investment in Praxis Precision Medicines, Inc. $PRAX

August 30, 2026 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Buy" from Brokerages

August 27, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High - What's Next?

August 18, 2026 | marketbeat.com

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

August 17, 2026 | finance.yahoo.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% Higher - Still a Buy?

August 17, 2026 | marketbeat.com

9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB

August 16, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

August 11, 2026 | theglobeandmail.com

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

August 11, 2026 | zacks.com

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

August 8, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Charles River Labs (CRL) and Senseonics Holdings (SENS)

August 8, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, ABVX, PRAX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

$118.64 +2.69 (+2.32%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$117.62 -1.02 (-0.86%)

As of 09/11/2026 07:50 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Kymera Therapeutics NASDAQ:KYMR

$114.96 -2.04 (-1.74%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$115.22 +0.27 (+0.23%)

As of 09/11/2026 07:30 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Precigen NASDAQ:PGEN

$6.85 +0.17 (+2.54%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$6.73 -0.12 (-1.81%)

As of 09/11/2026 07:53 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Praxis Precision Medicines NASDAQ:PRAX

$334.58 -3.99 (-1.18%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$334.76 +0.18 (+0.05%)

As of 09/11/2026 07:54 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PGEN, ABVX, PRAX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PGEN, ABVX, PRAX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PGEN, ABVX, PRAX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, ABVX, PRAX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

Kymera Therapeutics NASDAQ:KYMR

Precigen NASDAQ:PGEN

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PGEN, ABVX, PRAX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PGEN, ABVX, PRAX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PGEN, ABVX, PRAX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, ABVX, PRAX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

Kymera Therapeutics NASDAQ:KYMR

Precigen NASDAQ:PGEN

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools